Form 4: BioCardia CFO Acquires Shares and Warrants in Private Placement

David McClung, CFO of BioCardia, Inc., acquired 13,123 shares of common stock and warrants in a private placement on April 23, 2025.

Summary

• On April 23, 2025, BioCardia's CFO, David McClung, participated in a private placement.
• McClung acquired 13,123 shares of common stock at a price of $1.905 per share.
• He also received warrants to purchase 13,123 shares of common stock at an exercise price of $1.905.
• The warrants are exercisable immediately and expire on April 23, 2030.
• Following the transaction, McClung directly owns 43,131 shares of common stock and 21,456 warrants.

Sentiment

Score: 6

Explanation: Neutral sentiment. The document simply reports a transaction. The CFO's purchase is a positive signal, but it's a routine filing.

Positives

• The CFO's participation in the private placement could be seen as a sign of confidence in the company's future prospects.

Industry Context

Insider transactions are closely monitored by investors as they can provide insights into management's perspective on the company's valuation and future performance. A purchase by the CFO is generally viewed positively.

Stakeholder Impact

• The CFO's investment may positively influence shareholder sentiment.

Key Dates

Keywords

BioCardia, BCDA, David McClung, CFO, private placement, common stock, warrants, acquisition, Form 4, SEC